APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medulloblastoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Medulloblastoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174011600322 December 2025197 pages

Choose your research edition.

Industry ResearchMedulloblastoma Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Medulloblastoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Medulloblastoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medulloblastoma Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Medulloblastoma Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Medulloblastoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Medulloblastoma Drug include DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd and Progenics Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Medulloblastoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medulloblastoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medulloblastoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Medulloblastoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Medulloblastoma Drug Segment by Company

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Lipocure Ltd

MacroGenics Inc

NewLink Genetics Corp

Novogen Ltd

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Bristol-Myers Squibb Company

Bayer AG

Medulloblastoma Drug Segment by Type

Ipilimumab

Dianhydrogalactitol

Indoximod

IMP-5471

Others

Medulloblastoma Drug Segment by Application

Hospital

Clinic

Others

Medulloblastoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medulloblastoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medulloblastoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medulloblastoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Medulloblastoma Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Medulloblastoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Medulloblastoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Medulloblastoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Medulloblastoma Drug Industry Trends Table 2. Medulloblastoma Drug Industry Drivers Table 3. Medulloblastoma Drug Industry Opportunities and Challenges Table 4. Medulloblastoma Drug Industry Restraints Table 5. Global Medulloblastoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Medulloblastoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Medulloblastoma Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Medulloblastoma Drug Sales Market Share by Manufacturers Table 9. Global Medulloblastoma Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Medulloblastoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Medulloblastoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Medulloblastoma Drug Manufacturers, Product Type & Application Table 13. Global Medulloblastoma Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Medulloblastoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ipilimumab Table 17. Major Manufacturers of Dianhydrogalactitol Table 18. Major Manufacturers of Indoximod Table 19. Major Manufacturers of IMP-5471 Table 20. Major Manufacturers of Others Table 21. Global Medulloblastoma Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 23. Global Medulloblastoma Drug Sales by Type (2027-2032) & (k units) Table 24. Global Medulloblastoma Drug Sales Market Share by Type (2021-2026) Table 25. Global Medulloblastoma Drug Sales Market Share by Type (2027-2032) Table 26. Global Medulloblastoma Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Medulloblastoma Drug Revenue by Type (2021-2026) & (k units) Table 28. Global Medulloblastoma Drug Revenue by Type (2027-2032) & (k units) Table 29. Global Medulloblastoma Drug Revenue Market Share by Type (2021-2026) Table 30. Global Medulloblastoma Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Medulloblastoma Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 36. Global Medulloblastoma Drug Sales by Application (2027-2032) & (k units) Table 37. Global Medulloblastoma Drug Sales Market Share by Application (2021-2026) Table 38. Global Medulloblastoma Drug Sales Market Share by Application (2027-2032) Table 39. Global Medulloblastoma Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Medulloblastoma Drug Revenue by Application (2021-2026) & (k units) Table 41. Global Medulloblastoma Drug Revenue by Application (2027-2032) & (k units) Table 42. Global Medulloblastoma Drug Revenue Market Share by Application (2021-2026) Table 43. Global Medulloblastoma Drug Revenue Market Share by Application (2027-2032) Table 44. Global Medulloblastoma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Medulloblastoma Drug Sales by Region (2021-2026) & (k units) Table 46. Global Medulloblastoma Drug Sales Market Share by Region (2021-2026) Table 47. Global Medulloblastoma Drug Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Medulloblastoma Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 51. North America Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 52. Europe Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 54. Europe Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 61. Global Medulloblastoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Medulloblastoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Medulloblastoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Medulloblastoma Drug Revenue Market Share by Region (2021-2026) Table 65. Global Medulloblastoma Drug Revenue Market Share by Region (2027-2032) Table 66. DelMar Pharmaceuticals Inc Company Information Table 67. DelMar Pharmaceuticals Inc Business Overview Table 68. DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 70. DelMar Pharmaceuticals Inc Recent Development Table 71. Ignyta Inc Company Information Table 72. Ignyta Inc Business Overview Table 73. Ignyta Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Ignyta Inc Medulloblastoma Drug Product Portfolio Table 75. Ignyta Inc Recent Development Table 76. IMPACT Therapeutics Inc Company Information Table 77. IMPACT Therapeutics Inc Business Overview Table 78. IMPACT Therapeutics Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 80. IMPACT Therapeutics Inc Recent Development Table 81. Lipocure Ltd Company Information Table 82. Lipocure Ltd Business Overview Table 83. Lipocure Ltd Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Lipocure Ltd Medulloblastoma Drug Product Portfolio Table 85. Lipocure Ltd Recent Development Table 86. MacroGenics Inc Company Information Table 87. MacroGenics Inc Business Overview Table 88. MacroGenics Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. MacroGenics Inc Medulloblastoma Drug Product Portfolio Table 90. MacroGenics Inc Recent Development Table 91. NewLink Genetics Corp Company Information Table 92. NewLink Genetics Corp Business Overview Table 93. NewLink Genetics Corp Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. NewLink Genetics Corp Medulloblastoma Drug Product Portfolio Table 95. NewLink Genetics Corp Recent Development Table 96. Novogen Ltd Company Information Table 97. Novogen Ltd Business Overview Table 98. Novogen Ltd Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novogen Ltd Medulloblastoma Drug Product Portfolio Table 100. Novogen Ltd Recent Development Table 101. Ono Pharmaceutical Co Ltd Company Information Table 102. Ono Pharmaceutical Co Ltd Business Overview Table 103. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio Table 105. Ono Pharmaceutical Co Ltd Recent Development Table 106. Progenics Pharmaceuticals Inc Company Information Table 107. Progenics Pharmaceuticals Inc Business Overview Table 108. Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 110. Progenics Pharmaceuticals Inc Recent Development Table 111. Stemline Therapeutics Inc Company Information Table 112. Stemline Therapeutics Inc Business Overview Table 113. Stemline Therapeutics Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 115. Stemline Therapeutics Inc Recent Development Table 116. ThromboGenics NV Company Information Table 117. ThromboGenics NV Business Overview Table 118. ThromboGenics NV Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. ThromboGenics NV Medulloblastoma Drug Product Portfolio Table 120. ThromboGenics NV Recent Development Table 121. VBI Vaccines Inc Company Information Table 122. VBI Vaccines Inc Business Overview Table 123. VBI Vaccines Inc Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. VBI Vaccines Inc Medulloblastoma Drug Product Portfolio Table 125. VBI Vaccines Inc Recent Development Table 126. Bristol-Myers Squibb Company Company Information Table 127. Bristol-Myers Squibb Company Business Overview Table 128. Bristol-Myers Squibb Company Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio Table 130. Bristol-Myers Squibb Company Recent Development Table 131. Bayer AG Company Information Table 132. Bayer AG Business Overview Table 133. Bayer AG Medulloblastoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Bayer AG Medulloblastoma Drug Product Portfolio Table 135. Bayer AG Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Medulloblastoma Drug Distributors List Table 139. Medulloblastoma Drug Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Medulloblastoma Drug Product Image Figure 2. Global Medulloblastoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medulloblastoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Medulloblastoma Drug Sales (2021-2032) & (k units) Figure 5. Global Medulloblastoma Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Medulloblastoma Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ipilimumab Image Figure 9. Dianhydrogalactitol Image Figure 10. Indoximod Image Figure 11. IMP-5471 Image Figure 12. Others Image Figure 13. Global Medulloblastoma Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Medulloblastoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Medulloblastoma Drug Sales Market Share by Type (2021-2032) Figure 16. Global Medulloblastoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Medulloblastoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Medulloblastoma Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Medulloblastoma Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Medulloblastoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Medulloblastoma Drug Sales Market Share by Application (2021-2032) Figure 25. Global Medulloblastoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Medulloblastoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Medulloblastoma Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 42. China Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Medulloblastoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Medulloblastoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Medulloblastoma Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Medulloblastoma Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Medulloblastoma Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Medulloblastoma Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Medulloblastoma Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Medulloblastoma Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Medulloblastoma Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ipilimumab
  • Dianhydrogalactitol
  • Indoximod
  • IMP-5471
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • DelMar Pharmaceuticals Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • Novogen Ltd
  • Ono Pharmaceutical Co Ltd
  • Progenics Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • ThromboGenics NV
  • VBI Vaccines Inc
  • Bristol-Myers Squibb Company
  • Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medulloblastoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medulloblastoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Medulloblastoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Medulloblastoma Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Medulloblastoma Drug Market Dynamics
  1. 2.1 Medulloblastoma Drug Industry Trends
  2. 2.2 Medulloblastoma Drug Industry Drivers
  3. 2.3 Medulloblastoma Drug Industry Opportunities and Challenges
  4. 2.4 Medulloblastoma Drug Industry Restraints
3 Medulloblastoma Drug Market by Manufacturers
  1. 3.1 Global Medulloblastoma Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Medulloblastoma Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Medulloblastoma Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Medulloblastoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Medulloblastoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Medulloblastoma Drug Manufacturers, Product Type & Application
  7. 3.7 Global Medulloblastoma Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Medulloblastoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Medulloblastoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Medulloblastoma Drug Tier 1, Tier 2, and Tier 3
4 Medulloblastoma Drug Market by Type
  1. 4.1 Medulloblastoma Drug Type Introduction
  2. 4.1.1 Ipilimumab
  3. 4.1.2 Dianhydrogalactitol
  4. 4.1.3 Indoximod
  5. 4.1.4 IMP-5471
  6. 4.1.5 Others
  7. 4.2 Global Medulloblastoma Drug Sales by Type
  8. 4.2.1 Global Medulloblastoma Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Medulloblastoma Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Medulloblastoma Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Medulloblastoma Drug Revenue by Type
  12. 4.3.1 Global Medulloblastoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Medulloblastoma Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Medulloblastoma Drug Revenue Market Share by Type (2021-2032)
5 Medulloblastoma Drug Market by Application
  1. 5.1 Medulloblastoma Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Medulloblastoma Drug Sales by Application
  6. 5.2.1 Global Medulloblastoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medulloblastoma Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Medulloblastoma Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Medulloblastoma Drug Revenue by Application
  10. 5.3.1 Global Medulloblastoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Medulloblastoma Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Medulloblastoma Drug Revenue Market Share by Application (2021-2032)
6 Global Medulloblastoma Drug Sales by Region
  1. 6.1 Global Medulloblastoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medulloblastoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Medulloblastoma Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Medulloblastoma Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Medulloblastoma Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Medulloblastoma Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Medulloblastoma Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Medulloblastoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Medulloblastoma Drug Revenue by Region
  1. 7.1 Global Medulloblastoma Drug Revenue by Region
  2. 7.1.1 Global Medulloblastoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Medulloblastoma Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Medulloblastoma Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Medulloblastoma Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Medulloblastoma Drug Revenue (2021-2032)
  8. 7.2.2 North America Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Medulloblastoma Drug Revenue (2021-2032)
  11. 7.3.2 Europe Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Medulloblastoma Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Medulloblastoma Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Medulloblastoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 DelMar Pharmaceuticals Inc
  2. 8.1.1 DelMar Pharmaceuticals Inc Company Information
  3. 8.1.2 DelMar Pharmaceuticals Inc Business Overview
  4. 8.1.3 DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  6. 8.1.5 DelMar Pharmaceuticals Inc Recent Developments
  7. 8.2 Ignyta Inc
  8. 8.2.1 Ignyta Inc Company Information
  9. 8.2.2 Ignyta Inc Business Overview
  10. 8.2.3 Ignyta Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ignyta Inc Medulloblastoma Drug Product Portfolio
  12. 8.2.5 Ignyta Inc Recent Developments
  13. 8.3 IMPACT Therapeutics Inc
  14. 8.3.1 IMPACT Therapeutics Inc Company Information
  15. 8.3.2 IMPACT Therapeutics Inc Business Overview
  16. 8.3.3 IMPACT Therapeutics Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio
  18. 8.3.5 IMPACT Therapeutics Inc Recent Developments
  19. 8.4 Lipocure Ltd
  20. 8.4.1 Lipocure Ltd Company Information
  21. 8.4.2 Lipocure Ltd Business Overview
  22. 8.4.3 Lipocure Ltd Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lipocure Ltd Medulloblastoma Drug Product Portfolio
  24. 8.4.5 Lipocure Ltd Recent Developments
  25. 8.5 MacroGenics Inc
  26. 8.5.1 MacroGenics Inc Company Information
  27. 8.5.2 MacroGenics Inc Business Overview
  28. 8.5.3 MacroGenics Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MacroGenics Inc Medulloblastoma Drug Product Portfolio
  30. 8.5.5 MacroGenics Inc Recent Developments
  31. 8.6 NewLink Genetics Corp
  32. 8.6.1 NewLink Genetics Corp Company Information
  33. 8.6.2 NewLink Genetics Corp Business Overview
  34. 8.6.3 NewLink Genetics Corp Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NewLink Genetics Corp Medulloblastoma Drug Product Portfolio
  36. 8.6.5 NewLink Genetics Corp Recent Developments
  37. 8.7 Novogen Ltd
  38. 8.7.1 Novogen Ltd Company Information
  39. 8.7.2 Novogen Ltd Business Overview
  40. 8.7.3 Novogen Ltd Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novogen Ltd Medulloblastoma Drug Product Portfolio
  42. 8.7.5 Novogen Ltd Recent Developments
  43. 8.8 Ono Pharmaceutical Co Ltd
  44. 8.8.1 Ono Pharmaceutical Co Ltd Company Information
  45. 8.8.2 Ono Pharmaceutical Co Ltd Business Overview
  46. 8.8.3 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio
  48. 8.8.5 Ono Pharmaceutical Co Ltd Recent Developments
  49. 8.9 Progenics Pharmaceuticals Inc
  50. 8.9.1 Progenics Pharmaceuticals Inc Company Information
  51. 8.9.2 Progenics Pharmaceuticals Inc Business Overview
  52. 8.9.3 Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  54. 8.9.5 Progenics Pharmaceuticals Inc Recent Developments
  55. 8.10 Stemline Therapeutics Inc
  56. 8.10.1 Stemline Therapeutics Inc Company Information
  57. 8.10.2 Stemline Therapeutics Inc Business Overview
  58. 8.10.3 Stemline Therapeutics Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio
  60. 8.10.5 Stemline Therapeutics Inc Recent Developments
  61. 8.11 ThromboGenics NV
  62. 8.11.1 ThromboGenics NV Company Information
  63. 8.11.2 ThromboGenics NV Business Overview
  64. 8.11.3 ThromboGenics NV Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ThromboGenics NV Medulloblastoma Drug Product Portfolio
  66. 8.11.5 ThromboGenics NV Recent Developments
  67. 8.12 VBI Vaccines Inc
  68. 8.12.1 VBI Vaccines Inc Company Information
  69. 8.12.2 VBI Vaccines Inc Business Overview
  70. 8.12.3 VBI Vaccines Inc Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 VBI Vaccines Inc Medulloblastoma Drug Product Portfolio
  72. 8.12.5 VBI Vaccines Inc Recent Developments
  73. 8.13 Bristol-Myers Squibb Company
  74. 8.13.1 Bristol-Myers Squibb Company Company Information
  75. 8.13.2 Bristol-Myers Squibb Company Business Overview
  76. 8.13.3 Bristol-Myers Squibb Company Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio
  78. 8.13.5 Bristol-Myers Squibb Company Recent Developments
  79. 8.14 Bayer AG
  80. 8.14.1 Bayer AG Company Information
  81. 8.14.2 Bayer AG Business Overview
  82. 8.14.3 Bayer AG Medulloblastoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bayer AG Medulloblastoma Drug Product Portfolio
  84. 8.14.5 Bayer AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Medulloblastoma Drug Value Chain Analysis
  2. 9.1.1 Medulloblastoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Medulloblastoma Drug Production Mode & Process
  6. 9.2 Medulloblastoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Medulloblastoma Drug Distributors
  9. 9.2.3 Medulloblastoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst